[en] Background: Sclerostin, a 22-kDa protein secreted by osteocytes, acts as a potent inhibitor of osteoblast activity. In chronic kidney disease (CKD), sclerostin is a putative driver of the bone-vascular axis. However, large discrepancies between sclerostin assays have been described. Methods: We compared four different assays [Biomedica (BM), TecoMedical (TE), R&D (RD) and MesoScaleDiscovery (MSD)] in an analytical study and addressed the question whether bioassay choice affects the correlation between circulating sclerostin and clinical and biochemical determinants. Circulating sclerostin levels were determined in 39 prevalent dialysis patients and 82 non-dialysis patients referred for glomerular filtration rate measurement. Results: In the 82 non-dialysis patients, we observed large differences in median (interquartile range) sclerostin concentrations (in pg/mL): BM, 984 [interquartile range (IQR) 648]; TE, 629 (IQR 237); RD, 154 (IQR 84) and MSD, 36 (IQR 19). The concordance correlation coefficient between assays was poor (0.1-0.44). The same discrepancies were observed in dialysis patients. A significant negative rank correlation was found between glomerular filtration rate and sclerostin measured by BM and TE but not by MSD and RD. Associations between sclerostin and age, gender, weight or parathormone were also different according to the assay considered. Conclusions: Clinical inference relating sclerostin levels found in the general, CKD and dialysis populations is largely influenced by the assay used to measure this biomarker.
Disciplines :
Laboratory medicine & medical technology Urology & nephrology
Author, co-author :
DELANAYE, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Service de néphrologie
PAQUOT, Francois ; Centre Hospitalier Universitaire de Liège - CHU > Service de néphrologie
BOUQUEGNEAU, Antoine ; Centre Hospitalier Universitaire de Liège - CHU > Service de néphrologie
Blocki, Frank
Krzesinski, Jean-Marie ; Université de Liège - ULiège > Département des sciences cliniques > Néphrologie
Evenepoel, Pieter
Pottel, Hans
Cavalier, Etienne ; Université de Liège - ULiège > Département de pharmacie > Chimie médicale
Language :
English
Title :
Sclerostin and chronic kidney disease: the assay impacts what we (thought to) know.
Balemans W, Ebeling M, Patel N et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001; 10: 537-543
Robling AG, Niziolek PJ, Baldridge LA et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 2008; 283: 5866-5875
Galea GL, Lanyon LE, Price JS. Sclerostin's role in bone's adaptive response to mechanical loading. Bone 2017; 96: 38-44
McClung MR, Grauer A, Boonen S et al. Romosozumab in postmenopausal women with low bonemineral density. N Engl J Med 2014; 370: 412-420
Costa AG, Bilezikian JP, Lewiecki EM. The potential use of antisclerostin therapy in chronic kidney disease-mineral and bone disorder. Curr Opin Nephrol Hypertens 2015; 24: 324-329
Delanaye P, Cavalier E, Bouquegneau A et al. Sclerostin levels in CKD patients: An important, but not definitive, step on the way to clinical use. Kidney Int 2015; 88: 1221-1223
Schlieper G, Schurgers L, Brandenburg V et al. Vascular calcification in chronic kidney disease: an update. Nephrol Dial Transplant 2015; 31: 31-39
Brandenburg VM, D'Haese P, Deck A et al. From skeletal to cardiovascular disease in 12 steps\-The evolution of sclerostin as a major player in CKDMBD. Pediatr Nephrol 2016; 31: 195-206
Evenepoel P, D'haese P, Brandenburg V. Sclerostin and DKK1: new players in renal bone and vascular disease. Kidney Int 2015; 88: 235-240
Qureshi AR, Olauson H, Witasp A et al. Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification. Kidney Int 2015; 88: 1356-1364
Thambiah S, Roplekar R, Manghat P et al. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int 2012; 90: 473-480
Amrein K, Amrein S, Drexler C et al. Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults. J Clin EndocrinolMetab 2012; 97: 148-154
Gaudio A, Privitera F, Battaglia K et al. Sclerostin levels associated with inhibition of the Wnt/b-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. J Clin EndocrinolMetab 2012; 97: 3744-3750
Szulc P, Bertholon C, Borel O et al. Lower fracture risk in older men with higher sclerostin concentration: a prospective analysis from the MINOS study. J BoneMiner Res 2013; 28: 855-864
Claes KJ, Viaene L, Heye S et al. Sclerostin: another vascular calcification inhibitor. J Clin EndocrinolMetab 2013; 98: 3221-3228
Pelletier S, Dubourg L, CarlierMCet al. The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol 2013; 8: 819-823
Cejka D, Marculescu R, Kozakowski N et al. Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab 2014; 99: 248-255
van Lierop AH, Witteveen JE, Hamdy NA et al. Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur J Endocrinol 2010; 163: 833-837
Garnero P, Sornay-Rendu E, Munoz F et al. Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int 2013; 24: 489-494
Durosier C, Van LA, Ferrari S et al. Association of circulating sclerostin with bone mineral mass, microstructure, and turnover biochemical markers in healthy elderly men and women. J Clin Endocrinol Metab 2013; 98: 3873-3883
Cejka D, Herberth J, Branscum AJ et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 2011; 6: 877-882
Cejka D, Jager-Lansky A, Kieweg H et al. Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients. Nephrol Dial Transplant 2012; 27: 226-230
Malluche HH, Davenport DL, Cantor T et al. Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis. Clin J Am Soc Nephrol 2014; 9: 1254-1262
Jean G, Chazot C, Bresson E et al. High serum sclerostin levels are associated with a better outcome in haemodialysis patients. Nephron 2016; 132: 181-190
Brandenburg VM, Kramann R, Koos R et al. Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a crosssectional study. BMC Nephrol 2013; 14: 219
Morena M, Jaussent I, Dupuy AM et al. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications. Nephrol Dial Transplant 2015; 30: 1345-1356
Wang X-R, Yuan L, Zhang J-J et al. Serum sclerostin values are associated with abdominal aortic calcification and predict cardiovascular events in patients with chronic kidney disease stages 3-5D. Nephrology (Carlton) 2017; 22: 286-292
Evenepoel P,Meijers B, Bammens B et al. Sclerostin serum levels and vascular calcification progression in prevalent renal transplant recipients. J Clin EndocrinolMetab 2015; 100: 4669-4676
Delanaye P, Krzesinski J-M, Warling X et al. Clinical and biological determinants of sclerostin plasma concentration in hemodialysis patients. Nephron Clin Pract 2014; 128: 127-134
Viaene L, Behets GJ, Claes K et al. Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis. Nephrol Dial Transplant 2013; 28: 3024-3030
Drechsler C, Evenepoel P, VervloetMG et al. High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant 2015; 30: 288-293
Drake MT, Khosla S. Hormonal and systemic regulation of sclerostin. Bone 2017; 96: 8-17
Costa AG, Cremers S, Bilezikian JP. Sclerostin measurement in human disease: validity and current limitations. Bone 2017; 96: 24-28
Delanaye P, Ebert N, Melsom T et al. Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 1: how to measure glomerular filtration rate with iohexol? Clin Kidney J 2016; 9: 700-704
Delanaye P, Jouret F, Goff C et al. Concordance between iothalamate and iohexol plasma clearance. Am J Kidney Dis 2016; 68: 329-330
Bergstrom J, Wehle B. No change in corrected beta 2-microglobulin concentration after cuprophane haemodialysis. Lancet 1987; 1: 628-629
McNulty M, Singh RJ, Li X et al. Determination of serum and plasma sclerostin concentrations by enzyme-linked immunoassays. J Clin Endocrinol Metab 2011; 96: E1159-E1162
Piec I, Washbourne C, Tang J et al. How accurate is your sclerostine measurement? Comparsion between three commercially available sclerostin ELISA kits. Calcif Tissue Int 2016; 98: 546-555
Costa AG, Cremers S, Dworakowski E et al. Comparison of two commercially available ELISAs for circulating sclerostin. Osteoporos Int 2014; 25: 1547-1554
Mause SF, Deck A, Hennies M et al. Validation of commercially available ELISAs for the detection of circulating sclerostin in hemodialysis patients. Discoveries 2016; 4: e55
Moyses RM, Jamal SA, Graciolli FG et al. Can we compare serum sclerostin results obtained with different assays in hemodialysis patients? Int Urol Nephrol 2015; 47: 847-850
Van Lierop AH, Hamdy NAT, Van Bezooijen RL et al. The role of sclerostin in the pathophysiology of sclerosing bone dysplasias. Clin Rev Bone Miner Metab 2012; 10: 108-116
Cavalier E, Lukas P, Carlisi A et al. Aminoterminal propeptide of type I procollagen (PINP) in chronic kidney disease patients: the assay matters. Clin Chim Acta 2013; 425: 117-118
van Lierop AH, Hamdy NA, Hamersma H et al. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J BoneMiner Res 2011; 26: 2804-2811
Ishimura E, Okuno S, Ichii M et al. Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients. J Clin Endocrinol Metab 2014; 99: 4315-4320
Bielesz BO, Hempfing T, Kieweg H et al. Sclerostin declines during hemodialysis and appears in Dialysate. Blood Purif 2014; 38: 30-36
Jang M-G, Lee JY, Yang J-Y et al. Intermittent PTH treatment can delay the transformation of mature osteoblasts into lining cells on the periosteal surfaces. J BoneMinerMetab 2016; 34: 532-539
Bellido T, Saini V, Pajevic PD et al. Effects of PTH on osteocyte function. Bone 2013; 54: 250-257
Bruzzese A, Lacquaniti A, Cernaro V et al. Sclerostin levels in uremic patients: a link between bone and vascular disease. Ren Fail 2016; 38: 759-764
Lips L, Zuijdewijn CLM, et al. Serumsclerostin: relation with mortality and impact of hemodiafiltration. Nephrol Dial Transplant 2017; 32: 1217-1223
